Hepatitis C treatment: Mavyret approved as first eight-week treatment
by Press Release from Outbreak News Today on (#4R9AD)
The U.S. Food and Drug Administration today expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and ["]
The post Hepatitis C treatment: Mavyret approved as first eight-week treatment appeared first on Outbreak News Today.